Radiobiology

International Isotopes Inc. Announces It Has Acquired Full Ownership Of RadQual LLC

Retrieved on: 
Monday, July 12, 2021
Medicine, Neuroimaging, Medical physics, Medicinal radiochemistry, Medical specialties, Clinical medicine, Radiobiology, International Nuclear Information System, International Atomic Energy Agency, Single-photon emission computed tomography, iNiS, Nuclear medicine

In August 2017, this group of sellers acquired all of the units of RadQual not already held by INIS.

Key Points: 
  • In August 2017, this group of sellers acquired all of the units of RadQual not already held by INIS.
  • With this most recent acquisition, INIS will now own 100% of all outstanding units of RadQual, making RadQual a wholly-owned subsidiary of INIS.
  • RadQual is the premier global developer of quality control products for the nuclear medicine industry, focused principally on SPECT and PET imaging.
  • From RadQual 's inception in 2001, INIS has been the sole contract manufacturer of all RadQual products.

HistoSonics Announces Milestone As American Medical Association Issues Unique Category III CPT® Code For Histotripsy Of Liver

Retrieved on: 
Monday, July 12, 2021
Medical physics, Medicine, Physical sciences, Radiobiology, Applied sciences, Medical ultrasonography, High-intensity focused ultrasound, Magnetic resonance imaging, Cancer, CPT, Radiation therapy, Current Procedural Terminology

MINNEAPOLIS, July 12, 2021 /PRNewswire/ -- HistoSonics, ( www.histosonics.com ), the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, is pleased to announce that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver.

Key Points: 
  • MINNEAPOLIS, July 12, 2021 /PRNewswire/ -- HistoSonics, ( www.histosonics.com ), the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, is pleased to announce that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver.
  • Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy tissue in the liver without incisions, ionizing radiation or heat.
  • The new CPT code will become effective on January 1, 2022, at which time providers can utilize the code when performing histotripsy procedures on patients across the United States.
  • The new Category III CPT code, 0686T Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance will become effective January 1, 2022.

2021 Report on Gastrointestinal Radiation Toxicity Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Radiology, Pharmaceutical, Health, Health sciences, Pharmacology, Natural sciences, Physical sciences, Toxicology, Radiation therapy, Radioactivity, Radiobiology, Toxicity, Mechanism of action

The "Gastrointestinal Radiation Toxicity (Toxicology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Radiation Toxicity (Toxicology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Gastrointestinal Radiation Toxicity, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Radiation Toxicity and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Gastrointestinal Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.

Global Noninvasive Radiosurgery Robotic Systems Market to Reach $2.7 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Hospitals, Health, Medical devices, Albums, Neurosurgery, Radiobiology, Radiosurgery, Compound annual growth rate, Academic disciplines

The "Noninvasive Radiosurgery Robotic Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Noninvasive Radiosurgery Robotic Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Noninvasive Radiosurgery Robotic Systems estimated at US$991.4 Million in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 15.5% over the period 2020-2027.
  • The Noninvasive Radiosurgery Robotic Systems market in the U.S. is estimated at US$267.7 Million in the year 2020.
  • China, the world`s second largest economy, is forecast to reach a projected market size of US$605.6 Million by the year 2027 trailing a CAGR of 19.6% over the analysis period 2020 to 2027.

Violet Defense Highlights Benefits of Ultraviolet Technology for Combating Harmful Germs

Retrieved on: 
Tuesday, July 6, 2021
Hygiene, Medical specialties, Ultraviolet radiation, Electromagnetic radiation, Radiation, Water treatment, Radiobiology, Sterilization, Ultraviolet germicidal irradiation, Ultraviolet, Disinfectant, Salmonella

Violet Defense , a proprietary developer of germ-fighting UV technology, urges businesses to carefully vet any potential disinfection technology solutions for their effectiveness.

Key Points: 
  • Violet Defense , a proprietary developer of germ-fighting UV technology, urges businesses to carefully vet any potential disinfection technology solutions for their effectiveness.
  • Investing in and utilizing technologies without proper information in any industry is a risk, but it's especially true when it comes to combating bacteria and viruses.
  • Violet Defense continues to expand product options for deploying its patented technology.
  • Violet Defense uses UV disinfection to protect everyday spaces from harmful pathogens by killing up to 99.9% of E. coli, Salmonella, MRSA, C.

Global Single Photon Emission Computed Tomography (SPECT) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021
Technology, Medical devices, Other Technology, Cardiology, Radiology, Health, Pharmaceutical, General Health, Oncology, Neuroimaging, Medicine, Clinical medicine, Branches of biology, Radiobiology, Medical imaging, Emission computed tomography, Tomography, Single-photon, Advanced Cyclotron Systems, Draft:MILabs

The "Single Photon Emission Computed Tomography (SPECT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single Photon Emission Computed Tomography (SPECT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Single Photon Emission Computed Tomography (SPECT) estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 6.8% over the period 2020-2027.
  • This segment currently accounts for a 43.8% share of the global Single Photon Emission Computed Tomography (SPECT) market.
  • The U.S. Accounts for Over 36.1% of Global Market Size in 2020, While China is Forecast to Grow at a 9.4% CAGR for the Period of 2020-2027
    The Single Photon Emission Computed Tomography (SPECT) market in the U.S. is estimated at US$608.4 Million in the year 2020.

Huntsman Cancer Institute Begins Treatment with Mevion Compact Proton Therapy System

Retrieved on: 
Thursday, June 24, 2021
Medical devices, Hospitals, Health, Radiology, Oncology, Medical physics, Medicine, Health sciences, Applied sciences, Radiation therapy, Proton, Proton therapy, Radiobiology, Pencil-beam scanning, Therapy, Pencil, Indiana University Health Proton Therapy Center

Mevion Medical Systems today announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11th with the MEVION S250i Proton Therapy System.

Key Points: 
  • Mevion Medical Systems today announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11th with the MEVION S250i Proton Therapy System.
  • As the leading supplier of compact proton therapy systems in the United States, Mevion has been selected by more leading cancer centers, including NCI-Designated Cancer Centers, and has treated over 6,000 patients worldwide.
  • Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

Beloved Family Pet's Lung Cancer is Treated with Targeted Radiotherapy Using the Accuray Radixact® System with Synchrony® Technology

Retrieved on: 
Thursday, June 24, 2021
Medical physics, Medicine, Health effects of tobacco, Radiobiology, Radiation therapy, Radioactivity, Lung cancer, Physical sciences, Tomotherapy

Accuray (NASDAQ: ARAY) announced today that Mac, a Fox Terrier Mix, is doing well following radiotherapy treatment for recurrent lung cancer.

Key Points: 
  • Accuray (NASDAQ: ARAY) announced today that Mac, a Fox Terrier Mix, is doing well following radiotherapy treatment for recurrent lung cancer.
  • The TomoTherapy platform was originally invented at UW-Madison with the goal of developing a more accurate radiation therapy device for treating cancer.
  • He has been fighting lung cancer for two years now and has been a truly inspiring character the entire time.
  • Over the last two years, as Mac's cancer progressed, we were forced to remove around half of his lung capacity.

Cancer Patients Across the U.S. to Benefit from GenesisCare's Partnership with ViewRay, Inc.

Retrieved on: 
Thursday, June 24, 2021
Medical physics, Radiobiology, Medicine, Radiation therapy, Radioactivity, GenesisCare, Oncology, Pancreatic cancer, Nuclear physics, Health care

As a team, including ViewRay, The Pancreatic Cancer Research Fund, and the University of Oxford, we've already seen compelling results from the Compassionate Access Programme (in the UK)."

Key Points: 
  • As a team, including ViewRay, The Pancreatic Cancer Research Fund, and the University of Oxford, we've already seen compelling results from the Compassionate Access Programme (in the UK)."
  • In addition, by enabling continuous tracking of the target and surrounding healthy tissue, MRIdian can fluctuate the radiation beam if the patient moves.
  • We are excited our maturing partnership with GenesisCare will continue to revolutionize the radiation oncology landscape."
  • With more than 440 oncology and cardiology centers, GenesisCare offers radiotherapy at centers across Europe, Australia, and the United States.

Proton Therapy Opens in Utah

Retrieved on: 
Wednesday, June 23, 2021
Physical sciences, Medical physics, Physics, Natural sciences, Radiobiology, Radioactivity, Proton, Proton therapy, Radiation therapy, Ionizing radiation, Therapy, Radiation

"I have no doubt that the Senator Orrin G. Hatch Proton Therapy Center will play a critical role in this effort.

Key Points: 
  • "I have no doubt that the Senator Orrin G. Hatch Proton Therapy Center will play a critical role in this effort.
  • Proton therapy is a newer, more sophisticated type of radiation therapy that uses particles called protons instead of photons or electrons used in other radiation treatment.
  • Studies show patients have fewer and less serious side effects from proton therapy than traditional radiation therapy.
  • "With fewer than 40 proton therapy centers in the country, we recognized an incredible opportunity to deploy our extensive radiation therapy expertise at the University of Utah toward bringing this new resource to our patients.